SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
AI has the potential to transform cataract surgery outcomes for the better, according to a speaker. Surgical planning, predictive analytics for patient recovery and postoperative assessments are a few ...
Morning Overview on MSN
New study flags powerful drug target that could transform glaucoma treatment
Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...
January 15, 2026 - PRESSADVANTAGE - Lucent Vision has published a new educational resource titled “What Practice Offers ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
SightMD is proud to welcome two outstanding eye care professionals, William Boozan, MD and Tracey Rosenlicht, OD, to its growing network of providers. Their combined expertise enhances SightMD's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback